Palvella Therapeutics completes FDA pre-NDA meeting for QTORIN rapamycin

June 3, 2026 7:30 AM

Palvella Therapeutics Inc. (NASDAQ: PVLA) announced it completed a pre-New Drug Application meeting with the FDA for QTORIN 3.9% rapamycin ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found